Table 3.

Effect of GW9662 treatment on striatal dopamine and DOPAC levels. No difference is seen in MPTP induced reductions in dopamine and DOPAC levels between mice treated with GW9662 (5 mg/kg daily) or those receiving vehicle (5% DMSO — see text for details). Data are mean ± SEM, n = 4–5 mice per group. *p < 0.05, **p < 0.01, ***p < 0.001 compared to appropriate saline treated group (Kruskal–Wallis test with Mann Whitney U-post hoc tests).